No Need for Nausea Treatment for Most Patients on Kynmobi

No Need for Nausea Treatment for Most Patients on Kynmobi

305993

No Need for Nausea Treatment for Most Patients on Kynmobi

The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without needing antiemetics, or medicines to treat nausea and vomiting, according to a Sunovion press release. These findings are scheduled to be presented in two posters at the International…

You must be logged in to read/download the full post.